Skip to content
StackItSmart
BHuman cohort / observational
High riskCardiotoxicNeuropsychiatric

Trenbolone Enanthate

Tren E

Trenbolone enanthate ("Tren E") is a long-estered injectable form of trenbolone, a synthetic 19-nortestosterone (nandrolone-derived) anabolic-androgenic steroid (AAS) that was developed only as a veterinary/livestock growth promoter and has never been approved or clinically trialed in humans. It is used non-medically to increase muscle mass and reduce fat. There are no human safety, efficacy, or pharmacokinetic trials for this drug in people, so its human risk profile is inferred from case reports, from the broader AAS class, and from animal studies. It binds the androgen receptor roughly three times more strongly than testosterone and cannot be aromatized, but it is also progestogenic. Documented and biologically-plausible dangers include suppression of the body's own testosterone (hypogonadism/infertility), adverse cardiovascular changes (reduced heart pumping/relaxation function and coronary plaque seen across AAS users; case reports of heart attack and sudden death in trenbolone-containing stacks), cholestatic liver injury (case report), kidney injury (AAS-class case series), severe acne and gynecomastia, and neuropsychiatric effects. Because trenbolone-specific human evidence is limited to case reports and animal data, no claim of relative "safety" versus other AAS can be supported, and use should be discussed with a physician who can order monitoring.

Clinical readoutAAS · injectable-19nor
Hepatic strainModerate
CardiovascularHigh
HPTA suppressionHigh
Half-life
10.5 d
Route
Intramuscular
Evidence
B
Active
Estimated prolonged
10.5 d3.0 wk4.5 wk6.0 wk7.5 wk
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ No human pharmacokinetic study exists for trenbolone enanthate. The enanthate ester is a clandestine (non-pharmaceutical) preparation designed for slow release from an intramuscular depot; by analogy to other enanthate esters its release is prolonged over roughly 1-2 weeks, but this is an estimate, not a measured human value.
Pharmacology

Mechanism of action

Trenbolone (17β-hydroxyestra-4,9,11-trien-3-one) is a synthetic analog of nandrolone (19-nortestosterone) that acts as a potent agonist at the androgen receptor (AR), binding with roughly three times the affinity of testosterone. Unlike testosterone it is not a substrate for 5α-reductase (so it is not converted to more potent androgens in prostate/skin) and is not aromatized to estradiol; in animal models this produces "SARM-like" tissue-selective anabolic effects on muscle and bone with comparatively less prostate growth and less rise in hemoglobin at low doses (all preclinical, rat data). It also exhibits progestogenic (progesterone-receptor) activity typical of 19-nor compounds, which contributes to gonadotropin suppression and gynecomastia. Additional proposed mechanisms include altering endogenous growth-factor signaling and antagonizing glucocorticoid action. In neuronal cell cultures, trenbolone-induced toxicity is mediated through the androgen receptor. No human mechanistic confirmation exists.
Kinetics

Pharmacokinetics

Half-life

No human pharmacokinetic study exists for trenbolone enanthate. The enanthate ester is a clandestine (non-pharmaceutical) preparation designed for slow release from an intramuscular depot; by analogy to other enanthate esters its release is prolonged over roughly 1-2 weeks, but this is an estimate, not a measured human value.

Active duration

Estimated prolonged (on the order of 1-2+ weeks per injection) based on the long-chain ester; not established in humans. Parent trenbolone and its metabolites (e.g., 17-epitrenbolone) are detectable in urine, as shown in a post-mortem forensic case.

Route

Intramuscular (oil-based depot) injection.

Metabolism & clearance

After ester cleavage, trenbolone is metabolized hepatically; it is not 5α-reduced and not aromatized. Metabolites are excreted renally and are detectable in urine. Because no human clearance/washout data exist, these details are provided for clinician-guided monitoring and interpretation of bloodwork, not for any timing purpose.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Non-medical users take it to increase skeletal muscle mass and strength and to reduce body fat; in rats trenbolone enanthate increased androgen-sensitive muscle mass by 35-40% and reduced visceral fat (preclinical, not human efficacy data).
  • In animal models it partially protects against bone mineral density loss (preclinical).
  • Because it is not aromatized, it does not itself raise estradiol; however its progestogenic activity can still drive gynecomastia and libido/erectile changes.
  • Users commonly self-report night sweats, insomnia, reduced cardiovascular endurance, and mood changes; these are anecdotal/review-level rather than trial-confirmed.
Safety

Adverse effects by system

Cardiovascular

Adverse effects are expected based on the AAS class. In a controlled cross-sectional study of long-term AAS-using weightlifters, users had reduced left-ventricular systolic (mean LVEF 52% vs 63%) and diastolic function and greater coronary artery plaque volume, with plaque burden rising with cumulative lifetime AAS exposure. Trenbolone-specific case reports describe acute myocardial infarction in a young bodybuilder using trenbolone plus testosterone and nandrolone, and sudden cardiac death with left-ventricular hypertrophy in a multi-AAS user in whom trenbolone was detected. A trenbolone review reports hypertension and cardiac arrhythmia among users. Human trenbolone-specific evidence is limited to case reports.

Hepatic

Trenbolone enanthate is injectable and not 17α-alkylated, so the classic oral-steroid hepatotoxicity is not the expected pattern; however a liver-biopsy-confirmed case report attributes cholestatic hepatitis (jaundice, loss of appetite) to injectable trenbolone enanthate, showing hepatic injury can still occur. Data are limited to this case report.

Endocrine / HPTA

Strong suppression of the hypothalamic-pituitary-testicular axis is expected. As a 19-nor, progestogenic androgen, trenbolone suppresses LH/FSH and endogenous testosterone, causing testicular atrophy, impaired spermatogenesis, and infertility; recovery can be prolonged. This is established for the AAS class (reviews) rather than from trenbolone-specific human trials.

Reproductive

Gynecomastia (attributed to progestogenic activity) affects roughly one-third of users per a trenbolone review; testicular atrophy, reduced libido or erectile dysfunction, and reduced fertility are expected class effects. In animals, environmentally relevant trenbolone causes irreversible masculinization of fish, reflecting potent reproductive endocrine activity.

Neuropsychiatric

Neuropsychiatric effects (aggression/'roid rage,' irritability, mood disturbance, anxiety, depression, and dependence) are reported across the AAS class and in trenbolone reviews. In preclinical models trenbolone accumulates in brain (notably hippocampus) and induces neuronal apoptosis/neurodegeneration via androgen and estrogen receptors. Human trenbolone-specific psychiatric data are limited/absent.

Renal

A renal case series identified focal segmental glomerulosclerosis (FSGS), heavy proteinuria (mean ~10 g/day), and renal insufficiency in long-term AAS-using bodybuilders, with improvement after stopping and relapse on resumption in one patient. This is AAS-class case-series evidence, not trenbolone-specific.

Hematologic

Androgens as a class can raise hemoglobin/hematocrit (erythrocytosis), increasing thrombotic risk. In rat data, low-dose trenbolone raised hemoglobin less than supraphysiologic testosterone, but no human hematologic data for trenbolone exist. Treat polycythemia as a plausible class risk requiring CBC monitoring.

Dermatologic

Severe acne is common. A case report documents acne fulminans in a bodybuilder using AAS including trenbolone, and a trenbolone review reports severe acne and excessive body hair in a substantial fraction of users, plus stretch marks.

Recovery

HPTA suppression & recovery

Suppression: Expected strong suppression

As a progestogenic 19-nortestosterone AAS, trenbolone is expected to strongly suppress LH/FSH and endogenous testosterone, causing hypogonadism, testicular atrophy, and impaired fertility that may take months to recover and can be prolonged or, in some cases, incomplete. Post-cycle management of anabolic-steroid-induced hypogonadism has only low-quality evidence; published approaches (reviews) describe individualized use of a single selective estrogen receptor modulator (e.g., clomiphene) and/or hCG, but no dual-SERM protocol is endorsed here. Recovery is highly individual and depends on dose, duration, and agents used. This is not self-management guidance: anyone with suppression, low libido, depression, or fertility concerns should be evaluated and managed by an endocrinologist or andrologist with appropriate hormonal testing.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline and periodic lipid panel (total/LDL/HDL cholesterol, triglycerides)Complete blood count with hematocrit/hemoglobin (screen for erythrocytosis)Liver function tests (AST, ALT, ALP, bilirubin; GGT to interpret cholestasis)Renal function (serum creatinine/eGFR with the caveat that muscle mass elevates creatinine; cystatin C if available) and urine proteinBlood pressure monitoringReproductive hormones: total/free testosterone, LH, FSH, estradiol, and prolactinFasting glucose/HbA1cConsider cardiology evaluation (ECG, echocardiography) given documented LV dysfunction risk

Cadence: Establish baseline before any use; recheck bloodwork and blood pressure periodically during use (e.g., roughly every 8-12 weeks) and after discontinuation to document HPTA recovery, all under a clinician's direction.

Warning signs — seek care
  • Chest pain, shortness of breath, palpitations, or fainting - seek emergency care
  • Yellowing of skin/eyes, dark urine, right-upper-quadrant pain, appetite loss (possible liver injury)
  • Swelling, markedly reduced urine output, or foamy urine (possible kidney injury/proteinuria)
  • Severe headache, visual changes, or very high blood pressure
  • New or worsening aggression, depression, suicidal thoughts, or psychosis
  • Breast tissue growth or tenderness (gynecomastia)
  • Severe acne, especially rapidly worsening/ulcerating (acne fulminans)
  • Injection-site pain, swelling, redness, or spreading infection/abscess
Do not use if

Contraindications

  • No human therapeutic indication exists; it is a veterinary/non-approved compound with no established safe human dose.
  • Pre-existing or family history of cardiovascular disease, hypertension, dyslipidemia, coronary artery disease, cardiomyopathy, or arrhythmia.
  • Personal or strong family history of thrombosis, or baseline elevated hematocrit/polycythemia.
  • Liver disease or cholestasis.
  • Chronic kidney disease, proteinuria, or reduced renal function.
  • Desire for current or near-term fertility; existing hypogonadism.
  • History of hormone-sensitive cancer (e.g., prostate).
  • History of mood disorder, aggression, psychosis, or substance dependence.
  • Pregnancy and breastfeeding (potent androgen; virilizing); use in women carries high virilization risk.
  • Adolescents/young adults with open growth plates.
Combinations

Interaction profile

  • MajorWith another anabolic steroid: Additive cardiovascular strain
  • MajorWith a thermogenic stimulant: Additive cardiovascular strain
  • ModerateWith thyroid hormone: Additive cardiovascular strain
  • ModerateWith growth hormone: Additive cardiovascular strain
  • MajorWith another anabolic steroid: Blood / clotting
  • MajorWith a clot-promoting SERM: Blood / clotting
  • ModerateWith an aromatase inhibitor: Hormonal
  • ModerateWith an anabolic steroid: Hormonal
  • ModerateWith another 19-nor (progestogenic) steroid: Hormonal
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • This drug has no approved human use and no human safety/efficacy trials; the safest option is not to use it, and any use should be disclosed to a physician who can arrange monitoring.
  • Get baseline bloodwork (lipids, CBC/hematocrit, liver and kidney function, blood pressure, and reproductive hormones) before use and repeat periodically and after stopping.
  • Stop and seek emergency care for chest pain, breathlessness, palpitations, or fainting.
  • Stop and seek medical care for jaundice, dark urine, or right-upper-quadrant pain (possible liver injury), or for swelling/reduced urination/foamy urine (possible kidney injury).
  • Seek help urgently for new aggression, severe mood changes, depression, or suicidal thoughts.
  • Do not combine with other AAS, stimulants, or agents that raise cardiovascular or thrombotic risk; polypharmacy is prominent in the fatal case reports.
  • Never use during pregnancy/breastfeeding or when fertility is desired; virilization and fertility harm can be prolonged or irreversible.
  • Do not self-manage hormonal 'recovery.' Suppression, low libido, or infertility should be evaluated by an endocrinologist/andrologist; only single-SERM (not dual-SERM) approaches appear in the literature, and they require clinician oversight.
  • Injection-site pain, redness, or spreading swelling can signal infection/abscess and needs prompt medical attention.
  • Because human data are so limited, absence of reported harm does not mean safety - treat all class-level cardiovascular, hepatic, renal, endocrine, and psychiatric risks as applicable.
Evidence

Citations (15)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    Trenbolone is a synthetic 17β-hydroxyestra-4,9,11-trien-3-one AAS that binds the androgen receptor with ~3x the affinity of testosterone, is not 5α-reduced and is not aromatized, and is progestogenic/19-nor derived.

    ReviewTissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity.DOI 10.1016/j.steroids.2010.01.019 ↗

  2. 02

    In orchiectomized/intact rats, trenbolone enanthate produced tissue-selective anabolic effects: increased androgen-sensitive muscle mass by 35-40%, partial protection against bone loss and visceral fat gain, with less prostate growth and less hemoglobin rise at low doses than supraphysiologic testosterone.

    Preclinical17beta-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate.DOI 10.1152/ajpendo.00440.2010 ↗

  3. 03

    Injectable trenbolone enanthate can cause cholestatic hepatitis (biopsy-confirmed jaundice) even though it is not a 17α-alkylated oral steroid.

    Case reportA jaundiced bodybuilder: Cholestatic hepatitis as side effect of injectable anabolic-androgenic steroids.DOI 10.1080/02640414.2016.1265659 ↗

  4. 04

    Acute myocardial infarction occurred in a 35-year-old bodybuilder using trenbolone acetate, testosterone enanthate, and nandrolone.

    Case reportAcute Myocardial Infarct in a Young Bodybuilder Taking Anabolic Steroids: A Case Report.DOI 10.7759/cureus.95790 ↗

  5. 05

    Sudden cardiac death with left-ventricular hypertrophy occurred in a multi-AAS user in whom trenbolone (among other agents) was detected; long-term AAS use was implicated in the fatal cardiac pathology.

    Case reportDeath after misuse of anabolic substances (clenbuterol, stanozolol and metandienone).DOI 10.1016/j.forsciint.2019.109925 ↗

  6. 06

    Long-term AAS users show reduced LV systolic (LVEF 52% vs 63%) and diastolic function and greater coronary plaque volume, with plaque burden rising with cumulative lifetime AAS exposure.

    CohortCardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use.DOI 10.1161/CIRCULATIONAHA.116.026945 ↗

  7. 07

    Trenbolone use is associated with gynecomastia (~one-third of users), severe acne, excessive body hair, stretch marks, hypertension, cardiac arrhythmia, and injection-site complications; ~90% of users experience adverse effects.

    ReviewImpact of trenbolone on selected organs.DOI 10.5603/ep.99130 ↗

  8. 08

    Long-term AAS abuse in bodybuilders is associated with focal segmental glomerulosclerosis, heavy proteinuria, and renal insufficiency, improving after cessation and relapsing on resumption.

    Case seriesDevelopment of focal segmental glomerulosclerosis after anabolic steroid abuse.DOI 10.1681/ASN.2009040450 ↗

  9. 09

    Anabolic-steroid-induced hypogonadism causes testicular atrophy and impaired fertility; management has only low-quality evidence and involves individualized SERM and/or hCG use under specialist care.

    Meta-analysisAnabolic steroid-induced hypogonadism: diagnosis and treatment.DOI 10.1016/j.fertnstert.2014.02.002 ↗

  10. 10

    AAS use impairs spermatogenesis; recovery strategies (SERMs, hCG, aromatase inhibitors, rFSH) are described but need further study.

    ReviewAnabolic steroid misuse and male infertility: management and strategies to improve patient awareness.DOI 10.1080/17446651.2021.1921574 ↗

  11. 11

    Management strategies exist for AAS-induced hypogonadism and infertility, including fertility preservation/recovery approaches under andrology/endocrinology care.

    ReviewManagement of Anabolic Steroid-Induced Infertility: Novel Strategies for Fertility Maintenance and Recovery.DOI 10.5534/wjmh.190002 ↗

  12. 12

    Trenbolone induces neuronal apoptosis/toxicity in primary cortical cultures via the androgen receptor.

    PreclinicalToxic Impact of Anabolic Androgenic Steroids in Primary Rat Cortical Cell Cultures.DOI 10.1016/j.neuroscience.2018.11.035 ↗

  13. 13

    Trenbolone accumulates in brain (notably hippocampus), induces hippocampal neuronal apoptosis and contributes to neurodegeneration; recreational users are noted to self-inject large doses for long periods.

    Preclinical17beta-trenbolone, an anabolic-androgenic steroid as well as an environmental hormone, contributes to neurodegeneration.DOI 10.1016/j.taap.2014.11.007 ↗

  14. 14

    Acne fulminans was induced by anabolic steroids (including trenbolone) in a male bodybuilder.

    Case reportThe dark side of beauty: acne fulminans induced by anabolic steroids in a male bodybuilder.DOI 10.1001/archdermatol.2012.855 ↗

  15. 15

    Environmentally relevant 17β-trenbolone causes strong, irreversible masculinization in fish, illustrating potent androgenic/endocrine-disrupting reproductive activity.

    PreclinicalTrenbolone causes irreversible masculinization of zebrafish at environmentally relevant concentrations.DOI 10.1016/j.aquatox.2010.03.008 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice